Malley's Compounding Pharmacy (Columbia River Pharmacy, LLC), Richland, WA

Is Malley's Compounding Pharmacy (Columbia River Pharmacy, LLC) registered with the FDA as a 503B outsourcing facility?

No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.

Does Malley's Compounding Pharmacy (Columbia River Pharmacy, LLC) hold a Washington pharmacy license?

State board of pharmacy records for Washington are not checked: the Department of Health’s open dataset on data.wa.gov lists individual credentials but not pharmacy licenses, and its enforcement column has been removed for now; the department’s provider search is an interactive search, which this index does not use.

Has Malley's Compounding Pharmacy (Columbia River Pharmacy, LLC) had a state board action or FDA letter?

FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 state referral letter (Jul 19, 2021) and 1 FMD-145 letter (Jul 19, 2021) for Malley's Compounding Pharmacy (Columbia River Pharmacy, LLC). State board of pharmacy records for Washington are not checked: the Department of Health’s open dataset on data.wa.gov lists individual credentials but not pharmacy licenses, and its enforcement column has been removed for now; the department’s provider search is an interactive search, which this index does not use. The state referral and handoff letters above are FDA’s letters to the state, not board actions.

FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.

Names in FDA records
Columbia River Pharmacy, LLC; Malley's Compounding Pharmacy
Location
Richland, WA
Type as FDA labels it
503A
FDA 503B list
No matching record found
Form 483s on FDA’s actions page
1
Warning letters on FDA’s actions page
0
Latest action on that page
Jul 19, 2021
FDA Data Dashboard inspections
1 inspection: 1 VAI; 1 published Form 483
Form 483 text on this page
1 Form 483, 2 observations
State board records
Not checked

FDA inspections and letters

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Columbia River Pharmacy, LLC, (dba Malley's Compounding Pharmacy), a 503A facility, with 3 dated actions.

Document
Jul 19, 2021State referral letterState Referral Letter Issued 07/19/2021Not linked by FDA
Jul 19, 2021FMD-145 letterFMD-145 Letter Issued 07/19/2021Not linked by FDA
Aug 16, 2019Form 483483 Issued 08/16/2019FDA copy (archived)

A Form 483 lists investigator observations, not a final FDA determination. An untitled or FMD-145 letter states FDA’s view when it was issued.

FDA inspection classifications and published Form 483s

The FDA Data Dashboard, read Nov 15, 2026, lists Columbia River Pharmacy LLC, Richland, WA (FEI number 3005374721), matched to this page by exact name, city and state. It lists 1 inspection: 1 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.

Inspection endedClassificationProject area and product typeFEIInspection ID
Aug 16, 2019Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs)30053747211100402

Form 483s FDA has published for this site

FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483 for this site has 2 numbered observations in all. Each observation is quoted from the PDF as FDA numbered it. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection Aug 12, 2019 to Aug 16, 2019: 2 observations

Firm on the cover
Col umbia River Pharmacy LLC (DBA Malley's Compounding Pharmacy), 1906 George Washington Way, Richland, WA 99354-2308
FEI number
3005374721
Establishment type on the cover
Producer of Nonsterile Drug Products 1=======::::._ ----:---:----:.. :: --: :-:-:--- --'---- -::-::----:------:: .. ---:.... ----- =-==-=- =-=-=-- ,:- --:___ ... - ... ::: :::: =-=- -=-=-=- =::1, ___ _ ----- This document .lists observations made by the FDA representative(s) during the inspection of your facility. They are inspection al observations, and do not represent a final Agency determination regarding your compliance. If you have an objection regarding an observation, or have implemented, or plan lo implement, corrective action in response to an observation, you may discuss the objection or action with the FDA representative(s) during the inspection or submit this information to FDA at the address above. If you have any questions, please contact FDA at the phone number and address above.
FDA district office on the cover
DISTRICT ADDRESS AND PHONE NUM8ER 22215 26th Ave SE Suite 210 Bothell, WA 98021
Matched to this page by
FEI number on the cover; linked from actions page, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.

Observation 1

You produced hazardous drugs without providing adequate containment, segregation, cleaning of work surfaces and clean ing of utensils to prevent cross-contamination.

Specifically,

A. Hazardous bulk drug substances (ie: hormones) are stored together with non-hazardous bulk drug substances within your compounding lab.

B. A deactivating agent is not used to clean non-dedicated equipment (ie: hoods and utensils) to prevent cross­contamination.

C. Non-dedicated <Redacted B4> hoods are designed in a way that the exhaust is vented back into the compounding room.

D. Glassware (ie: graduated cylinders, mortar and pestles) is stored on open shelves by the end of the compound lab with no door present.

Observation 2

Your facility design allowed the influx of poor quality air into a higher classified area.

Specifically,

A. The compounding lab has two doorways. The door to one of the doorways was observed propped open leading to the hallway and storage area. The other doorway had no door present and a fan was observed blowing air from the general pharmacy area into the compounding lab.

State board of pharmacy records

State board of pharmacy records for Washington are not checked: the Department of Health’s open dataset on data.wa.gov lists individual credentials but not pharmacy licenses, and its enforcement column has been removed for now; the department’s provider search is an interactive search, which this index does not use.

This page restates FDA’s lists. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.